Markets

Insider Trading

Hedge Funds

Retirement

Opinion

11 Most Promising Psychedelic Stocks According to Hedge Funds

In this piece, we will take a look at the 11 most promising psychedelic stocks according to hedge funds. If you want to skip our overview of the psychedelic industry and the latest news, then you can take a look at the 5 Most Promising Psychedelic Stocks.

The ability to use chemicals to alter one’s mind has been in play for human beings for hundreds if not thousands of years. Psychedelics have been used for thousands of years by ancient societies, and even in 2023, they remain a cultural significance for tribes in Latin America and Africa. One of the more well-known cultural psychedelics is the Ayahuasca, used by the indigenous peoples in South America.

A psychedelic is not your everyday drug or controlled substance. Unlike marijuana, cocaine, or other substances, psychedelics are quite strong, and for their users, they are a gateway to an alternate reality. Apart from Ayahuasca, other psychedelics such as N, N-dimethyltryptamine (DMT), Lysergic acid diethylamide (LSD), Mescaline, and Psilocin are chemically derived and purified forms that are quite strong as well.

There are several different use cases for psychedelics. One of the most well-known uses is for recreational purposes, with party goers often amplifying their experience by transporting themselves into their own ‘metaverse’. However, another use case for these drugs that has grown in popularity recently is medicinal use. A growing awareness about mental illnesses and diseases like depression has also made researchers look for alternative ways to treat these diseases. Depression, for those out of the loop, is a chemical imbalance in a patient’s brain, and psychiatry typically seeks to treat it through a combination of medicine and behavioral therapy. These drugs typically regulate brain chemicals called serotonin and dopamine due to their effects on the mood.

These days though, researchers are also studying if the use of psychedelics can prove to be beneficial for mental health patients. While it’s come under the media’s radar recently, research about the potential benefits of psychedelics for patients with mental health diseases is actually quite old. It first took place in the 1980s, but the steam died down once psychedelics were classified as Schedule I substances under the Controlled Substance Act.

Since it’s a controlled substance, medical research surrounding psychedelics is also limited to strictly controlled environments. After all, you cannot just simply go to your pharmacy and buy LSD, and as a result, researchers have to make sure that they follow stringent requirements when working with these substances. Additionally, as 2023 heads to a close, it has also marked a shift in the tide when it comes to psychedelic research as universities all over the world have now established their own centers. Universities such as Johns Hopkins, Imperial College, University of Texas, the Mount Sinai Medical School, and others have dedicated psychedelic research centers. At the same time, 2023 also saw Australia take the lead in the medical use of psychedelics as a treatment for treatment resistant depression and post traumatic stress disorder. Treatment resistant depression is one of the toughest diseases to beat since standard depression medication such as Selective Serotonin Reuptake Inhibitors (SSRIs) or Monoamine oxidase inhibitors (MAOIs) often fails to improve the patient’s quality of life.

The psychedelics authorized for medical use in Australia are substances that are typically found in the party drug ecstasy and magic mushrooms. Since the medicinal uses of psychedelics are still limited, market research reports peg the industry with double digit growth rates. For instance, one report that looks at the ‘advanced visualization market’ and it estimates that the market worth $2.3 billion in 2022 and is expected to grow at a compounded annual growth rate (CAGR) of 13.3% to be worth $6.4 billion by the end of 2030. The research identifies several factors that will prove to be tailwinds for the global psychedelic market. These include a rise in therapeutic applications, a rising awareness about mental health, a growing prevalence of mental health disorders, and growing research into these drugs.

Naturally, where there’s a market, there are companies seeking to use it to make money. This is also the case with the global psychedelic market, as several firms are developing the drugs and running programs to evaluate their efficacy. For instance, COMPASS Pathways plc (NASDAQ:CMPS) shared the results of its COMP360 psilocybin treatment’s phase 2 clinical trial in December 2023. In this study, 22 patients with post traumatic stress disorders resulting from adult trauma were evaluated. According to the company, the test subjects were given a 25mg single dose of the COMP360, and they did not face any adverse reactions or side effects. Compass Pathways is also running a phase 3 study program of its drug, which it states is the largest of its kind to be ever conducted. Crucially for current and future researchers though, since the trials are legally approved, their data is recorded and stored for further research to create a new avenue of treatment for depression patients.

Today, we’ll look at the most promising psychedelic stocks according to hedge funds. The top three psychedelic stocks are Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), Alkermes plc (NASDAQ:ALKS), and Sage Therapeutics, Inc. (NASDAQ:SAGE).

Our Methodology

To make our list of the most promising psychedelic stocks according to hedge funds, we ranked the holdings of the AdvisorShares Psychedelics ETF by the number of hedge funds that had invested in them as of Q3 2023 end.

11 Most Promising Psychedelic Stocks According to Hedge Funds

11. NRx Pharmaceuticals, Inc. (NASDAQ:NRXP)

Number of Hedge Fund Investors In Q3 2023: 3

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) is an American biotechnology company headquartered in Wilmington, Delaware. The firm is developing treatments for depression and other ailments. It progressed in its efforts to use ketamine for suicidality in depression patients in December 2023 by signing an agreement with Columbia University to share the data.

By the end of Q3 2023, three out of the 910 hedge funds part of Insider Monkey’s database had held a stake in NRx Pharmaceuticals, Inc. (NASDAQ:NRXP). It joins Alkermes plc (NASDAQ:ALKS), Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), and Sage Therapeutics, Inc. (NASDAQ:SAGE) in our list of the most promising psychedelic stocks according to hedge funds.

10. Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)

Number of Hedge Fund Investors In Q3 2023: 3

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) is developing treatments for anxiety, ADHD, and autism. The firm has beaten analyst EPS estimates in two out of its three latest quarters and the stock is rated Strong Buy on average.

As of September 2023 end, three out of the 910 hedge funds profiled by Insider Monkey were the firm’s shareholders. Israel Englander’s Millennium Management was Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)’s largest shareholder due to its $743,297 stake.

9. Atai Life Sciences N.V. (NASDAQ:ATAI)

Number of Hedge Fund Investors In Q3 2023: 5

Atai Life Sciences N.V. (NASDAQ:ATAI) is a German biotechnology firm developing treatments for mental health disorders and opioid addiction. It ended its third quarter with $209 million in cash and equivalents which the company believes should be sufficient to fund its operations until 2026.

By the end of this year’s third quarter, five out of the 910 hedge funds covered by Insider Monkey had invested in Atai Life Sciences N.V. (NASDAQ:ATAI). The firm’s biggest investor is John Overdeck and David Siegel’s Two Sigma Advisors as it owns 107,500 shares that are worth $138,675.

8. Seelos Therapeutics, Inc. (NASDAQ:SEEL)

Number of Hedge Fund Investors In Q3 2023: 5

Seelos Therapeutics, Inc. (NASDAQ:SEEL) is developing ketamine based treatments for people with suicidal ideation and major depression. Its shares were under stress in December 2023 when the company announced that it plans to raise more capital through a mixed offering.

Insider Monkey dug through 910 hedge funds for their September quarter of 2023 shareholdings and found that five had invested in the company. Seelos Therapeutics, Inc. (NASDAQ:SEEL)’s largest shareholder is Hal Mintz’s Sabby Capital courtesy of its $2.1 million investment.

7. Vistagen Therapeutics, Inc. (NASDAQ:VTGN)

Number of Hedge Fund Investors In Q3 2023: 7

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) is a small biotechnology company headquartered in San Francisco, California. The firm’s investors were dealt with shocking news in December 2023 when Jefferies downgraded the stock to Hold from Buy and slashed the price target to $0.20 from $8.

As 2023’s third quarter ended, seven among the 910 hedge funds tracked by Insider Monkey were Vistagen Therapeutics, Inc. (NASDAQ:VTGN)’s shareholders. Out of these, the biggest investor was Egen Atkinson and Michael Kramarz’s Commodore Capital through its $8.2 million stake.

6. GH Research PLC (NASDAQ:GHRS)

Number of Hedge Fund Investors In Q3 2023: 10

GH Research PLC (NASDAQ:GHRS) is an Irish firm seeking to use DMT to develop treatments for mental health ailments. Even though the firm has beaten analyst EPS in all three of its latest quarters, the stock is down by more than 40% year to date.

Ten out of the 910 hedge funds surveyed by Insider Monkey during Q3 2023 had invested in the company. GH Research PLC (NASDAQ:GHRS)’s largest shareholder is Mark Lampert’s Biotechnology Value Fund / BVF Inc as it owns $93.2 million worth of shares.

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), GH Research PLC (NASDAQ:GHRS), Alkermes plc (NASDAQ:ALKS), and Sage Therapeutics, Inc. (NASDAQ:SAGE) are some top hedge fund psychedlic stocks.

Click here to continue reading and check out 5 Most Promising Psychedelic Stocks.

Suggested articles:

Disclosure: None. 11 Most Promising Psychedelic Stocks According to Hedge Funds is originally published on Insider Monkey.

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

AI is eating the world—and the machines behind it are ravenous.

Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink.

Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and building the digital future. But there’s one urgent question few are asking:

Where will all of that energy come from?

AI is the most electricity-hungry technology ever invented. Each data center powering large language models like ChatGPT consumes as much energy as a small city. And it’s about to get worse.

Even Sam Altman, the founder of OpenAI, issued a stark warning:

“The future of AI depends on an energy breakthrough.”

Elon Musk was even more blunt:

“AI will run out of electricity by next year.”

As the world chases faster, smarter machines, a hidden crisis is emerging behind the scenes. Power grids are strained. Electricity prices are rising. Utilities are scrambling to expand capacity.

And that’s where the real opportunity lies…

One little-known company—almost entirely overlooked by most AI investors—could be the ultimate backdoor play. It’s not a chipmaker. It’s not a cloud platform. But it might be the most important AI stock in the US owns critical energy infrastructure assets positioned to feed the coming AI energy spike.

As demand from AI data centers explodes, this company is gearing up to profit from the most valuable commodity in the digital age: electricity.

The “Toll Booth” Operator of the AI Energy Boom

  • It owns critical nuclear energy infrastructure assets, positioning it at the heart of America’s next-generation power strategy.
  • It’s one of the only global companies capable of executing large-scale, complex EPC (engineering, procurement, and construction) projects across oil, gas, renewable fuels, and industrial infrastructure.
  • It plays a pivotal role in U.S. LNG exportation—a sector about to explode under President Trump’s renewed “America First” energy doctrine.

Trump has made it clear: Europe and U.S. allies must buy American LNG.

And our company sits in the toll booth—collecting fees on every drop exported.

But that’s not all…

As Trump’s proposed tariffs push American manufacturers to bring their operations back home, this company will be first in line to rebuild, retrofit, and reengineer those facilities.

AI. Energy. Tariffs. Onshoring. This One Company Ties It All Together.

While the world is distracted by flashy AI tickers, a few smart investors are quietly scooping up shares of the one company powering it all from behind the scenes.

AI needs energy. Energy needs infrastructure.

And infrastructure needs a builder with experience, scale, and execution.

This company has its finger in every pie—and Wall Street is just starting to notice.

Wall Street is noticing this company also because it is quietly riding all of these tailwinds—without the sky-high valuation.

While most energy and utility firms are buried under mountains of debt and coughing up hefty interest payments just to appease bondholders…

This company is completely debt-free.

In fact, it’s sitting on a war chest of cash—equal to nearly one-third of its entire market cap.

It also owns a huge equity stake in another red-hot AI play, giving investors indirect exposure to multiple AI growth engines without paying a premium.

And here’s what the smart money has started whispering…

The Hedge Fund Secret That’s Starting to Leak Out

This stock is so off-the-radar, so absurdly undervalued, that some of the most secretive hedge fund managers in the world have begun pitching it at closed-door investment summits.

They’re sharing it quietly, away from the cameras, to rooms full of ultra-wealthy clients.

Why? Because excluding cash and investments, this company is trading at less than 7 times earnings.

And that’s for a business tied to:

  • The AI infrastructure supercycle
  • The onshoring boom driven by Trump-era tariffs
  • A surge in U.S. LNG exports
  • And a unique footprint in nuclear energy—the future of clean, reliable power

You simply won’t find another AI and energy stock this cheap… with this much upside.

This isn’t a hype stock. It’s not riding on hope.

It’s delivering real cash flows, owns critical infrastructure, and holds stakes in other major growth stories.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 100+% Return within 12 to 24 months.

We’re now offering month-to-month subscriptions with no commitments.

For a ridiculously low price of just $9.99 per month, you can unlock our in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!


No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!

A New Dawn is Coming to U.S. Stocks

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…